The COPD STARR2 study
THE COPD STARR 2 TRIAL
Delivering personalised care in the management of exacerbations of chronic obstructive pulmonary disease: A multi-centre randomised clinical trial
Ethics Ref: 17/LO/1135
EudraCT Number: 2017-001586-24
Background: Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) are debilitating and a major NHS Burden. Treat guidelines recommend oral steroids and antibiotics but failure to respond to is a common, AE-COPD aetiology and response to treatment is varied. Current ‘one-size-fits-all’ approaches are unsatisfactory.
Hypothesis: A personalised stratified treatment approach in AE-COPD in primary care using near-patient testing to derive phenotypes of COPD is superior to current strategies.
Study Deign: Double-blinded randomised placebo control study
Expected outcomes: Treatment failure rates are reduced in AE-COPD receiving phenotype-specific-near-patient testing directed therapy.
Anticipated benefits: Health economics benefit and guideline changes in AE-COPD management.
Who to contact if you want more information
Professor Mona Bafadhel (study Doctor) Tel 01865 612898
Joanne Davies and Helen Jeffers (study Nurses) Tel 07769 280289/07554 436726